Bristol-Myers Squibb Company (BMY) EV/EBIT Ratio: 12.14x
Is Bristol-Myers Squibb Company’s EV/EBIT ratio high or low?
Bristol-Myers Squibb Company's EV/EBIT ratio of 12.14x is 36% below its 5-year average of 18.89x, near the low end of its 5-year range (9.29x–36.51x).
As of Thursday, June 11, 2026. 6.92% above its 12-month average of 11.35x.
BMY EV/EBIT Ratio Chart
BMY Average EV/EBIT Ratio Chart
BMY Current vs Average EV/EBIT Ratio Chart
BMY EV/EBIT Ratio Metrics
EV/EBIT RATIO
12.14x
EV/EBIT RATIO AVG TTM
11.35x
EV/EBIT RATIO AVG 3Y
15.41x
EV/EBIT RATIO AVG 5Y
18.89x
EV/EBIT RATIO AVG 10Y
22.21x
EV/EBIT RATIO AVG 15Y
25.48x
EV/EBIT RATIO AVG 20Y
22.54x
CURRENT VS TTM AVG
+6.92%
CURRENT VS 3Y AVG
-21.20%
CURRENT VS 5Y AVG
-35.74%
CURRENT VS 10Y AVG
-45.33%
CURRENT VS 15Y AVG
-52.36%
CURRENT VS 20Y AVG
-46.13%
BMY Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bristol-Myers Squibb Company (BMY) | $116.13B | 12.14x | 11.35x | 15.41x | 18.89x |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.59B | 22.87x | 26.41x | 24.92x | 21.76x |
| Danaher Corporation (DHR) | $126.39B | 27.62x | 30.65x | 32.50x | 29.68x |
| CVS Health Corporation (CVS) | $126.70B | 32.55x | 28.87x | 19.89x | 18.76x |
| Medtronic plc (MDT) | $102.72B | 19.23x | 23.68x | 24.37x | 26.81x |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 45.37x | 63.25x | 73.01x | 67.77x |
| Elevance Health Inc. (ELV) | $86.47B | 14.59x | 11.84x | 13.42x | 14.42x |
| Pfizer Inc. (PFE) | $149.61B | 14.37x | 12.24x | 29.84x | 23.37x |
| Cigna Corporation (CI) | $77.92B | 10.72x | 11.17x | 12.56x | 13.06x |
| Abbott Laboratories (ABT) | $155.75B | 22.39x | 27.94x | 30.32x | 27.86x |
Bristol-Myers Squibb Company EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for Bristol-Myers Squibb Company (BMY)?
- The EV/EBIT ratio for BMY stock is 12.14x.
- Is Bristol-Myers Squibb Company's EV/EBIT ratio high or low?
- Bristol-Myers Squibb Company's EV/EBIT ratio of 12.14x is 36% below its 5-year average of 18.89x, near the low end of its 5-year range (9.29x–36.51x).
- What is the TTM average EV/EBIT ratio for Bristol-Myers Squibb Company (BMY)?
- The TTM average EV/EBIT ratio for BMY stock is 11.35x.
- What is the 3Y average EV/EBIT ratio for Bristol-Myers Squibb Company (BMY)?
- The 3Y average EV/EBIT ratio for BMY stock is 15.41x.
- What is the 5Y average EV/EBIT ratio for Bristol-Myers Squibb Company (BMY)?
- The 5Y average EV/EBIT ratio for BMY stock is 18.89x.
- What is the 10Y average EV/EBIT ratio for Bristol-Myers Squibb Company (BMY)?
- The 10Y average EV/EBIT ratio for BMY stock is 22.21x.
- What is the 15Y average EV/EBIT ratio for Bristol-Myers Squibb Company (BMY)?
- The 15Y average EV/EBIT ratio for BMY stock is 25.48x.
- What is the 20Y average EV/EBIT ratio for Bristol-Myers Squibb Company (BMY)?
- The 20Y average EV/EBIT ratio for BMY stock is 22.54x.
Bristol-Myers Squibb Company EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-11 | 12.14x |
| 2026-06-10 | 11.93x |
| 2026-06-09 | 12.08x |
| 2026-06-08 | 11.93x |
| 2026-06-05 | 12.21x |
| 2026-06-04 | 12.10x |
| 2026-06-03 | 11.79x |
| 2026-06-02 | 11.74x |
| 2026-06-01 | 11.83x |
| 2026-05-29 | 12.19x |
| 2026-05-28 | 12.15x |
| 2026-05-27 | 12.25x |
| 2026-05-26 | 12.33x |
| 2026-05-22 | 12.57x |
| 2026-05-21 | 12.58x |
| 2026-05-20 | 12.41x |
| 2026-05-19 | 12.38x |
| 2026-05-18 | 12.21x |
| 2026-05-15 | 12.16x |
| 2026-05-14 | 12.12x |
| 2026-05-13 | 12.06x |
| 2026-05-12 | 12.07x |
| 2026-05-11 | 11.94x |
| 2026-05-08 | 12.02x |
| 2026-05-07 | 12.04x |
| 2026-05-06 | 12.09x |
| 2026-05-05 | 12.15x |
| 2026-05-04 | 12.22x |
| 2026-05-01 | 12.36x |
| 2026-04-30 | 12.75x |
| 2026-04-29 | 12.17x |
| 2026-04-28 | 12.27x |
| 2026-04-27 | 12.20x |
| 2026-04-24 | 12.35x |
| 2026-04-23 | 12.40x |
| 2026-04-22 | 12.36x |
| 2026-04-21 | 12.46x |
| 2026-04-20 | 12.41x |
| 2026-04-17 | 12.58x |
| 2026-04-16 | 12.39x |
| 2026-04-15 | 12.22x |
| 2026-04-14 | 12.25x |
| 2026-04-13 | 12.24x |
| 2026-04-10 | 12.33x |
| 2026-04-09 | 12.47x |
| 2026-04-08 | 12.43x |
| 2026-04-07 | 12.18x |
| 2026-04-06 | 12.45x |
| 2026-04-02 | 12.49x |
| 2026-04-01 | 12.83x |
| 2026-03-31 | 12.66x |
| 2026-03-30 | 12.51x |
| 2026-03-27 | 12.32x |
| 2026-03-26 | 12.46x |
| 2026-03-25 | 12.38x |
| 2026-03-24 | 12.13x |
| 2026-03-23 | 12.07x |
| 2026-03-20 | 12.15x |
| 2026-03-19 | 12.25x |
| 2026-03-18 | 12.45x |
| 2026-03-17 | 12.51x |
| 2026-03-16 | 12.51x |
| 2026-03-13 | 12.41x |
| 2026-03-12 | 12.39x |
| 2026-03-11 | 12.55x |
| 2026-03-10 | 12.58x |
| 2026-03-09 | 12.66x |
| 2026-03-06 | 12.60x |
| 2026-03-05 | 12.67x |
| 2026-03-04 | 12.93x |
| 2026-03-03 | 12.75x |
| 2026-03-02 | 12.93x |
| 2026-02-27 | 12.94x |
| 2026-02-26 | 12.73x |
| 2026-02-25 | 12.76x |
| 2026-02-24 | 12.81x |
| 2026-02-23 | 12.76x |
| 2026-02-20 | 12.66x |
| 2026-02-19 | 12.60x |
| 2026-02-18 | 12.51x |
| 2026-02-17 | 12.61x |
| 2026-02-13 | 12.67x |
| 2026-02-12 | 12.53x |
| 2026-02-11 | 12.54x |
| 2026-02-10 | 11.54x |
| 2026-02-09 | 11.53x |
| 2026-02-06 | 11.71x |
| 2026-02-05 | 11.34x |
| 2026-02-04 | 11.06x |
| 2026-02-03 | 10.82x |
| 2026-02-02 | 10.81x |
| 2026-01-30 | 10.68x |
| 2026-01-29 | 10.57x |
| 2026-01-28 | 10.62x |
| 2026-01-27 | 10.76x |
| 2026-01-26 | 10.62x |
| 2026-01-23 | 10.62x |
| 2026-01-22 | 10.67x |
| 2026-01-21 | 10.60x |
| 2026-01-20 | 10.56x |
| 2026-01-16 | 10.71x |
| 2026-01-15 | 10.91x |
| 2026-01-14 | 10.97x |
| 2026-01-13 | 10.81x |
| 2026-01-12 | 10.79x |
| 2026-01-09 | 10.80x |
| 2026-01-08 | 10.81x |
| 2026-01-07 | 10.93x |
| 2026-01-06 | 10.59x |
| 2026-01-05 | 10.39x |
| 2026-01-02 | 10.45x |
| 2025-12-31 | 10.52x |
| 2025-12-30 | 10.56x |
| 2025-12-29 | 10.54x |
| 2025-12-26 | 10.62x |
| 2025-12-24 | 10.63x |
| 2025-12-23 | 10.57x |
| 2025-12-22 | 10.63x |
| 2025-12-19 | 10.56x |
| 2025-12-18 | 10.43x |
| 2025-12-17 | 10.46x |
| 2025-12-16 | 10.56x |
| 2025-12-15 | 10.57x |
| 2025-12-12 | 10.29x |
| 2025-12-11 | 10.11x |
| 2025-12-10 | 10.12x |
| 2025-12-09 | 10.03x |
| 2025-12-08 | 10.18x |
| 2025-12-05 | 10.25x |
| 2025-12-04 | 10.23x |
| 2025-12-03 | 10.08x |
| 2025-12-02 | 9.68x |
| 2025-12-01 | 9.82x |
| 2025-11-28 | 9.82x |
| 2025-11-26 | 9.83x |
| 2025-11-25 | 9.80x |
| 2025-11-24 | 9.61x |
| 2025-11-21 | 9.38x |
| 2025-11-20 | 9.34x |
| 2025-11-19 | 9.32x |
| 2025-11-18 | 9.50x |
| 2025-11-17 | 9.47x |
| 2025-11-14 | 9.44x |
| 2025-11-13 | 9.74x |
| 2025-11-12 | 9.80x |
| 2025-11-11 | 9.75x |
| 2025-11-10 | 9.53x |
| 2025-11-07 | 9.45x |
| 2025-11-06 | 9.44x |
| 2025-11-05 | 9.42x |
| 2025-11-04 | 9.29x |
| 2025-11-03 | 9.35x |
| 2025-10-31 | 9.36x |
| 2025-10-30 | 9.29x |
| 2025-10-29 | 10.05x |
| 2025-10-28 | 10.08x |
| 2025-10-27 | 10.18x |
| 2025-10-24 | 10.25x |
| 2025-10-23 | 10.25x |
| 2025-10-22 | 10.34x |
| 2025-10-21 | 10.36x |
| 2025-10-20 | 10.21x |
| 2025-10-17 | 10.21x |
| 2025-10-16 | 10.18x |
| 2025-10-15 | 10.21x |
| 2025-10-14 | 10.24x |
| 2025-10-13 | 10.20x |
| 2025-10-10 | 10.27x |
| 2025-10-09 | 10.39x |
| 2025-10-08 | 10.36x |
| 2025-10-07 | 10.38x |
| 2025-10-06 | 10.46x |
| 2025-10-03 | 10.51x |
| 2025-10-02 | 10.56x |
| 2025-10-01 | 10.84x |
| 2025-09-30 | 10.46x |
| 2025-09-29 | 10.30x |
| 2025-09-26 | 10.30x |
| 2025-09-25 | 10.18x |
| 2025-09-24 | 10.30x |
| 2025-09-23 | 10.42x |
| 2025-09-22 | 10.44x |
| 2025-09-19 | 10.44x |
| 2025-09-18 | 10.54x |
| 2025-09-17 | 10.63x |
| 2025-09-16 | 10.66x |
| 2025-09-15 | 10.66x |
| 2025-09-12 | 10.64x |
| 2025-09-11 | 10.85x |
| 2025-09-10 | 10.79x |
| 2025-09-09 | 10.80x |
| 2025-09-08 | 10.72x |
| 2025-09-05 | 10.79x |
| 2025-09-04 | 10.72x |
| 2025-09-03 | 10.85x |
| 2025-09-02 | 10.83x |
| 2025-08-29 | 10.80x |
| 2025-08-28 | 10.75x |
| 2025-08-27 | 10.87x |
| 2025-08-26 | 10.80x |
| 2025-08-25 | 10.79x |
| 2025-08-22 | 10.92x |
| 2025-08-21 | 11.00x |
| 2025-08-20 | 10.97x |
| 2025-08-19 | 10.99x |
| 2025-08-18 | 10.96x |
| 2025-08-15 | 11.00x |
| 2025-08-14 | 10.90x |
| 2025-08-13 | 10.91x |
| 2025-08-12 | 10.69x |
| 2025-08-11 | 10.59x |
| 2025-08-08 | 10.59x |
| 2025-08-07 | 10.50x |
| 2025-08-06 | 10.41x |
| 2025-08-05 | 10.58x |
| 2025-08-04 | 10.50x |
| 2025-08-01 | 10.31x |
| 2025-07-31 | 10.16x |
| 2025-07-30 | 12.27x |
| 2025-07-29 | 12.43x |
| 2025-07-28 | 12.55x |
| 2025-07-25 | 12.73x |
| 2025-07-24 | 12.82x |
| 2025-07-23 | 12.83x |
| 2025-07-22 | 12.65x |
| 2025-07-21 | 12.40x |
| 2025-07-18 | 12.53x |
| 2025-07-17 | 12.66x |
| 2025-07-16 | 12.49x |
| 2025-07-15 | 12.35x |
| 2025-07-14 | 12.52x |
| 2025-07-11 | 12.43x |
| 2025-07-10 | 12.74x |
| 2025-07-09 | 12.58x |
| 2025-07-08 | 12.47x |
| 2025-07-07 | 12.36x |
| 2025-07-03 | 12.44x |
| 2025-07-02 | 12.58x |
| 2025-07-01 | 12.55x |
| 2025-06-30 | 12.33x |
| 2025-06-27 | 12.34x |
| 2025-06-26 | 12.39x |
| 2025-06-25 | 12.40x |
| 2025-06-24 | 12.46x |
| 2025-06-23 | 12.44x |
| 2025-06-20 | 12.43x |
| 2025-06-18 | 12.43x |
| 2025-06-17 | 12.50x |
| 2025-06-16 | 12.77x |
| 2025-06-13 | 12.97x |
| 2025-06-12 | 13.15x |
| 2025-06-11 | 13.05x |
| 2025-06-10 | 13.01x |
| 2025-06-09 | 12.83x |
| 2025-06-06 | 12.72x |
| 2025-06-05 | 12.62x |
| 2025-06-04 | 12.64x |
| 2025-06-03 | 12.66x |
| 2025-06-02 | 12.79x |
| 2025-05-30 | 12.70x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner